A consortium of more than 30 private and public organisations has launched to facilitate the transition towards outcomes-focused healthcare systems across Europe.
A consortium of more than 30 private and public organisations has launched to facilitate the transition towards outcomes-focused healthcare systems across Europe. Health iQ will join bodies such as National Institute for Health and Care Excellence (NICE), Imperial College London, the European Cancer Patient Coalition and the Norwegian Institute of Public Health, as well as pharmaceutical companies such as Amgen, Bayer, Boehringer Ingelheim, Celgene, Janssen, Eli Lilly, MSD, Novo Nordisk, Pfizer, Roche, Sanofi and UCB. The London School of Economics and Political Science (LSE) will act as Project Coordinator and Novartis will act as Project Lead.
The consortium will coordinate the Big Data for Better Outcomes (BD4BO) programme which was launched with the objective of harnessing the opportunities of big data to promote patient-centred, outcomes-focused healthcare in Europe and to develop innovative methods for integrating, analysing, and using big data.
The aim is to identify and address opportunities for data-driven healthcare system transformation in order to fully exploit the transformative potential of big data in healthcare.
Commenting on the news Jilani Gulam, Chief Executive of Health iQ, said:
“This initiative combining patients, regulators, innovators and industry is a welcome innovation that will drive better healthcare outcomes across Europe, leading to significant value in patient well-being”.
The full press release can be viewed at LSE Health - Click here
Notes to editors
Health iQ is a privately-owned company based in London specializing in insight into real world healthcare data based on an outstanding heritage of working in the NHS. It now works with more than half of the top 100 global Life Science firms.